Eli Lilly and Company(LLY) is having a Dividend Yield of 2.59% with the Annual cash Dividend per share of $2.04. The last quarter cash dividend per share pay out was $0.51. Eli Lilly and Company has a 5 year average dividend yield of 3.33% and the stock has a Indicated annual dividend of $2.08. Eli Lilly and Company(LLY) formally announced its most recent dividend on December 13, 2016 with a Dividend per share of $0.52. The new indicated annual dividend based on announced dividend per share is $2.08. The dividend yield based on the forward looking indicated annual dividend is 2.59%. Eli Lilly and Company(LLY) has the most recent dividend payout ratio of 0.58 with a 5-year average payout ratio of 0.58. The 5 year historical dividend growth of Eli Lilly and Company(LLY) is at the rate of 0.97% while the R-Squared dividend growth is 0.75. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Eli Lilly and Company (NYSE:LLY) witnessed a decline in the market cap on Thursday as its shares dropped 0.26% or 0.21 points. After the session commenced at $80.05, the stock reached the higher end at $80.38 while it hit a low of $79.41. With the volume soaring to 3,630,059 shares, the last trade was called at $80.04. The company has a 52-week high of $83.785. The company has a market cap of $88,360 million and there are 1,103,948,230 shares in outstanding. The 52-week low of the share price is $64.18. Shares of Eli Lilly and Company rose by 3.7% in the last five trading days and 3.93% for the last 4 weeks. Eli Lilly and Company is up 4.21% in the last 3-month period. Year-to-Date the stock performance stands at 9.56%.
Currently the company Insiders own 0.2% of Eli Lilly and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.36% . Institutional Investors own 75.15% of Eli Lilly and Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.36%. Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Alfonso G Zulueta (SVP& Pres., Emerging Markets) sold 15,000 shares at 77.66 per share price.On Feb 3, 2017, Derica W Rice (EVP-Global Services and CFO) sold 11,162 shares at 77.22 per share price.On Feb 3, 2017, Donald A Zakrowski (Chief Accounting Officer) sold 2,000 shares at 77.52 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Eli Lilly and Co was Upgraded by Morgan Stanley to Overweight on Dec 16, 2016.
Eli Lilly and Co Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.95 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.98. The company had revenue of $5760.50 million for the quarter, compared to analysts expectations of $5554.54 million. The companys revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.